News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
228,455 Results
Type
Article (5419)
Company Profile (17)
Press Release (223019)
Section
Business (82964)
Career Advice (573)
Deals (15185)
Drug Delivery (11)
Drug Development (19523)
Employer Resources (32)
FDA (3782)
Job Trends (4067)
News (121857)
Policy (7939)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (314)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14978)
ALS (20)
Alzheimer's disease (251)
Antibody-drug conjugate (ADC) (11)
Approvals (3799)
Artificial intelligence (41)
Autoimmune disease (3)
Automation (3)
Bankruptcy (98)
Best Places to Work (3000)
Biosimilars (25)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (48)
Cancer (447)
Cardiovascular disease (42)
Career advice (486)
Career pathing (4)
CAR-T (31)
Cell therapy (102)
Cervical cancer (2)
Clinical research (16411)
Collaboration (172)
Compensation (169)
Complete response letters (2)
COVID-19 (350)
CRISPR (7)
C-suite (105)
Cystic fibrosis (16)
Data (529)
Depression (5)
Diabetes (51)
Diagnostics (2065)
Digital health (3)
Diversity, equity & inclusion (13)
Drug discovery (15)
Drug pricing (20)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (41010)
Editorial (2)
Employer branding (7)
Employer resources (33)
Events (38123)
Executive appointments (317)
FDA (4039)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (188)
Gene editing (16)
Generative AI (2)
Gene therapy (51)
GLP-1 (127)
Government (474)
Guidances (17)
Healthcare (5230)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (15)
Indications (6)
Infectious disease (367)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (16)
Interviews (73)
IPO (7881)
IRA (4)
Job creations (1154)
Job search strategy (430)
Kidney cancer (7)
Labor market (5)
Layoffs (104)
Leadership (7)
Legal (2578)
Liver cancer (17)
Lung cancer (54)
Lymphoma (31)
Management (10)
Manufacturing (51)
MASH (28)
Medical device (3899)
Medtech (3900)
Mergers & acquisitions (7508)
Metabolic disorders (135)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (1)
Neuroscience (344)
NextGen: Class of 2025 (1772)
Non-profit (775)
Northern California (934)
Now hiring (4)
Obesity (61)
Opinion (36)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (14)
Parkinson's disease (27)
Partnered (4)
Patents (22)
Patient recruitment (29)
Peanut (5)
People (24831)
Pharmaceutical (5)
Pharmacy benefit managers (19)
Phase I (4824)
Phase II (7051)
Phase III (5786)
Pipeline (557)
Policy (14)
Postmarket research (687)
Preclinical (1893)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (106)
Rare diseases (67)
Real estate (1895)
Recruiting (9)
Regulatory (5262)
Reports (14)
Research institute (314)
Resumes & cover letters (114)
Rett syndrome (3)
Schizophrenia (21)
Series A (29)
Series B (24)
Sickle cell disease (7)
Southern California (703)
Special edition (2)
Spinal muscular atrophy (30)
Sponsored (6)
Startups (1020)
Stomach cancer (1)
Supply chain (10)
Tariffs (4)
United States (7116)
Vaccines (48)
Venture capitalists (2)
Weight loss (26)
Women's health (2)
Worklife (1)
Date
Today (37)
Last 7 days (169)
Last 30 days (746)
Last 365 days (10128)
2025 (3025)
2024 (11191)
2023 (13317)
2022 (18838)
2021 (19951)
2020 (18562)
2019 (13634)
2018 (10510)
2017 (10200)
2016 (9321)
2015 (12262)
2014 (9697)
2013 (7790)
2012 (8420)
2011 (8896)
2010 (8739)
Location
Africa (207)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (2)
Asia (11580)
Australia (1637)
California (1953)
Canada (698)
China (71)
Colorado (83)
Connecticut (92)
Delaware (30)
Europe (24895)
Florida (276)
Georgia (34)
Idaho (23)
Illinois (119)
India (7)
Indiana (67)
Iowa (1)
Japan (73)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (40)
Maryland (226)
Massachusetts (1561)
Michigan (86)
Minnesota (140)
Mississippi (1)
Missouri (24)
Montana (16)
Nebraska (12)
Nevada (23)
New Hampshire (15)
New Jersey (578)
New Mexico (5)
New York (476)
North Carolina (327)
North Dakota (2)
Northern California (934)
Ohio (56)
Oklahoma (5)
Oregon (4)
Pennsylvania (350)
Puerto Rico (1)
Rhode Island (16)
South America (358)
South Carolina (5)
Southern California (703)
Tennessee (40)
Texas (230)
Utah (61)
Virginia (48)
Washington D.C. (12)
Washington State (175)
West Virginia (2)
Wisconsin (22)
228,455 Results for "cvs caremark corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 30, 2024
·
12 min read
Biotech Beach
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
Arcutis Biotherapeutics, Inc. announced that ZORYVE® cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5.
July 17, 2023
·
5 min read
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
·
2 min read
·
Tristan Manalac
Business
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report
CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis.
July 12, 2024
·
2 min read
·
Tristan Manalac
Pharmacy benefit managers
House Oversight Chair Calls on PBM Execs to Correct Testimonies
The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.
August 29, 2024
·
2 min read
·
Tristan Manalac
Pharmacy benefit managers
Cigna to Remove AbbVie’s Humira From Formularies, Putting More Pressure on Blockbuster
Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.
August 27, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CVS Health to hold first quarter 2025 earnings conference call
April 3, 2025
·
1 min read
Press Releases
CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer
April 8, 2025
·
5 min read
Press Releases
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025
March 20, 2025
·
3 min read
Press Releases
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
March 12, 2025
·
5 min read
1 of 22,846
Next
